Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

611
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
611
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

748
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
748
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

705
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
705
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

574
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
574
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

529
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
529
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

434
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
434

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential role of tirabrutinib as part of an optimal treatment strategy for lymphomatosis cerebri: illustrative case.

Journal of neurosurgery. Case lessons·2026
Same author

Prevalence of Developmental Dysplasia of the Hip in Japanese Patients with Adolescent Idiopathic Scoliosis: Comparison of Conventional and Age-Adjusted Criteria.

Children (Basel, Switzerland)·2026
Same author

In-hospital mortality following tracheostomy in very preterm infants with bronchopulmonary dysplasia: A Japanese nationwide retrospective cohort study.

Pediatrics and neonatology·2026
Same author

Quantitative spectroscopic analysis of talaporfin sodium fluorescence: Utility in fluorescence-guided surgery and detection of invasive tumor cells in glioblastoma.

Surgical neurology international·2026
Same author

Incidence of RSV- and Influenza-Associated Hospitalizations With Community-Acquired Pneumonia and Other Acute Respiratory Infection Among Adults in Japan in 2022-2024: APSG-J2 Study.

Influenza and other respiratory viruses·2026
Same author

Guidelines for the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis 2025 Supplement.

The Journal of dermatology·2026

Related Experiment Video

Updated: Mar 14, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K

Hypophosphatemia-induced Cardiomyopathy.

Nobuhiro Ariyoshi1, Masayuki Nogi1, Akika Ando1

  • 1Department of Internal Medicine, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii.

The American Journal of the Medical Sciences
|September 22, 2016
PubMed
Summary

Hypophosphatemia, a condition of low phosphate levels, can impact heart function, potentially causing cardiomyopathy. Severe cases may show improved cardiac performance after phosphate correction, highlighting its role in heart failure.

Keywords:
CardiomyopathyHeart failureHypophosphatemia

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.5K

Related Experiment Videos

Last Updated: Mar 14, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.5K

Area of Science:

  • Cardiology
  • Electrophysiology
  • Critical Care Medicine

Background:

  • Limited research exists on hypophosphatemia's cardiac effects.
  • Hypophosphatemia may be an underrecognized cause of heart failure.

Purpose of the Study:

  • To review the association between hypophosphatemia and cardiac function.
  • To raise awareness of hypophosphatemia-induced cardiomyopathy as a reversible cause of heart failure.

Main Methods:

  • Systematic literature search of MEDLINE and PubMed (1971-March 2015).
  • Inclusion of 11 primary studies (case reports, case-control, animal studies).

Main Results:

  • Hypophosphatemia may cause cardiomyopathy via ATP depletion and reduced erythrocyte 2,3-DPG.
  • Left ventricular function may improve after correcting severe hypophosphatemia.
  • No significant improvement in mild-to-moderate hypophosphatemia.

Conclusions:

  • Hypophosphatemia is a potential cause of reversible cardiomyopathy.
  • Further clinical studies are needed to analyze cardiac function and hypophosphatemia.
  • Recognition of hypophosphatemia is crucial for managing heart failure.